NEW YORK (TheStreet) -- CHANGE IN RATINGS
rated new Hold at Jefferies. $33 price target. There is excess capacity in flexible packaging, which could hurt pricing.
rated new Buy at Soleil Securities. $9 price target. Visibility should improve by the end of the year, which could drive multiple expansion.
Illinois Tool Works
downgraded at Goldman from Buy to Neutral. $50 price target. Consensus estimates have caught up with the company's earnings potential.
downgraded at Barclays to Underweight from Overweight. Concerned about the accelerating bed losses as well as reimbursement pressure. Price target cut to $21 from $29.
rated new Buy at Jefferies. $41 price target. Company is not receiving enough credit for its potential operating leverage.
downgraded at Barclays to Equal Weight from Overweight on bed losses and reimbursement pressure. Price target lowered to $10 from $19.
downgraded at Baird to Neutral. See little upside potential to the deal reached with Rank Group. $33 price target.
downgraded at Deutsche from Buy to Hold. $33 price target. See limited upside potential, given the current merger agreement.
downgraded at Citigroup from Buy to Hold. Valuation call, based on a $33.25 price target.
upgraded at Barclays to Overweight from Equal Weight. Wafer market fundamentals will remain robust in 2011. Price target jumped to $12 from $10.
Trina Solar Limited
upgraded at Barclays to Overweight from Equal Weight. 2011 demand outlook is improving. Price target increased to $30 from $21.
STOCK COMMENTS / EPS CHANGES
estimates increased at Morgan Stanley through 2011. Company continues to benefit from leverage to the industrial sector. Overweight rating and $33 price target.
estimates upped at Goldman through 2011. Company raised its guidance and is keeping a lid on costs. Sell rating and $22 price target.
price target increased at BofA/Merrill to $55 from $50. AMT can maintain its outperformance as the market gravitates to strong, stable secular growth stories. Reiterate Buy rating.
Abercrombie & Fitch
numbers lowered at UBS. Shares of ANF now seen reaching $38. Estimates also cut, as higher inventory levels could lead to further promotional activity. Neutral rating.
price target raised at BofA/Merrill to $105 from $94 on higher 2011 EBITDA estimate and lower net debt. Reiterate Buy rating.
numbers boosted at Jefferies. Shares of ENDP now seen reaching $44. Estimates also upped, given less expected generic competition. Buy rating.
estimates boosted at Goldman through 2011. Company is seeing better hardware and PC sales. Neutral rating and $21 price target.
price target improved at Barclays. HD price target raised by a dollar to $36. Strong margin performance and improving trends. Maintain Overweight rating.
estimates increased at Jefferies through 2012. Low interest rates and improving credit trends should support better business. Buy rating and $33 price target.
target reduced at Kaufman to $51. CEO transition adds risk to the story. Buy rating.
target upped at Deutsche to $38. Turkey business is strong and pork packing margins are improving. Sell rating.
estimates, target raised at FBR. Shares of LOW now seen reaching $23. Estimates also increased, given a better sales outlook. Outperform rating.
Las Vegas Sands
price target boosted at BofA/Merrill to $34 from $31 on higher gaming volume at Macau. Maintain Buy rating.
estimates, target raised at Morgan Stanley. Shares of POT now seen reaching $160. Estimates also increased. Overweight rating.
Research in Motion
numbers cut at Oppenheimer. Shares of RIMM now seen reaching $58. Estimates also lowered, as checks show a mixed reception for the new Torch device. Outperform rating.
estimates, target raised at Goldman. Shares of SKS now seen reaching $7.30. Estimates were also increased, given the company's higher realized sales and margins. Sell rating.
estimates, target increased at Goldman. SLH estimates were raised through 2012. Company should benefit from a weaker dollar. Neutral rating and new $40 price target.
target, estimate boosted at Barclays by a dollar to $13. 2011 outlook improving. 2011 EPS estimate lifted to $1.47 from $1.40. Maintain Equal Weight rating.
estimates raised at Citigroup through 2011. Ratiopharm acquisition should add to earnings. Buy rating and $72 price target.
estimates cut at Goldman through 2012. Company is seeing lower margins in the coming quarters. Neutral rating and $46 price target.
estimates upped at Morgan Stanley through 2012. Company should see a recovery in the do-it-yourself market and is also a top supplier to CAT and DE. Overweight rating and $39 price target.
estimates boosted at UBS through 2012. Company is buying back shares and keeping a tight lid on costs. Buy rating and $60 price target.
This article was written by a staff member of TheStreet.